Morris Kelley, M.D.

Morris E. Kelley M.D.

Clinic/Medical Office

CHI St. Vincent Heart Clinic Arkansas - North Little Rock


4000 Richards Road, Suite A
North Little Rock, AR 72117 (directions)



Address 2

1300 Braden Street
Jacksonville, AR 72076 (directions)

Address 3

130 JF Boulevard
Lonoke, AR 72086 (directions)

Address 4

15111 Hwy 165
Scott, AR 72142 (directions)


Cardiology, Interventional Cardiology, Nuclear Cardiology, Peripheral Vascular Cardiology

Board Certifications

Internal Medicine, Cardiovascular Disease, Interventional Cardiology


University of Arkansas for Medical Sciences


Interventional Cardiology, University Medical Center, Camden, NJ, Adult Cardiology Fellowship Training Program, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV

Hospital Affiliation

CHI St. Vincent North

Additional Information

Honors/Achievements: Thelma V. Owen Memorial Clinical Vignette Poster Winner. Joan C. Edwards School of Medicine. Marshall University 20th Annual Research Day – 2007; University of Arkansas for Medical Sciences Class of 1976 Alumni Scholarship – 1999; National Medical Fellowships Scholarship – 1997; Phi Beta Kappa Honors Society; Golden Key Honors Society

Research: Diabetes Is Associated With Alterations In The Dystrophin Glycoprotein Complex Composition In Heart Muscle. Morris E. Kelley M.D., M. Taimoor Gill, M.D., Marina Flaskas, M.D., Sarath Meduru, Devashish H. Desai, Kevin M. Rice, Paulette S. Wehner, M.D., and Eric R. Blough, Ph.D. Joan C. Edwards School of Medicine, Marshall University; CURRENT/OASIS 7 Trial: Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early invasive strategy. Co-investigator; A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Co-investigator
Eisai 202 - A Randomized, Double-Blind, Placebo-Contolled Study of the Safety and Tolerability of E5555, and its Effects on Clinical Events and Biomarkers in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. Co-investigator

Professional Societies/Memberships: American College of Cardiology – Associate Member; Association of Black Cardiologists; Pulaski County Medical Society; Arkansas Medical Society; Alpha Phi Alpha Fraternity, Inc.

Go Back